PANX2

Across TCGA pan-cancer cohorts, PANX2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PANX2 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PANX2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PANX2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

CCRCC, HNSC, and GBM are the cancer types where PANX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.571	0.967	<.001	38	view →
HNSC	DFS	Tertile	III,IV	0.878	0.607	.020	8	view →
GBM	OS	Median	All	0.234	0.669	.020	5	view →
LSCC	DFS	Quartile	II,III,IV	0.929	0.810	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PANX2–CCRCC (DFS)

Open the CCRCC breakdown →